1 minute read
MEDICAL ONCOLOGY
OPEN TO RECRUITMENT — AUSTRALIA & NEW ZEALAND
Abbrev. Title
BGB-A317-LBL-007-201
Protocol Title
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
BIG 16-05 AFT-27
WO39391 IMPassion030
Alexandra
A Phase 3, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple Negative
Breast Cancer
BIG 16-05 AFT-27
WO39391 IMPassion030
Alexandra
A Phase 3, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple Negative
Breast Cancer
BIG 19-02 BCT2002 DECRESCENDO
De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
BIG 19-02 BCT2002 DECRESCENDO
De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
BO29554 B.FAST
A Phase 2/3 Multicentre Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harbouring Actionable Somatic Mutations Detected in Blood
CA224-104 RELATIVITY A Phase 2 Randomized Double-Blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy Vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers
CL001_559
A Phase 1 First In Human, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of CCX559 in Subjects with Solid Tumours
